Drug Profile
Terbinafine transdermal - Hisamitsu
Alternative Names: HTU-520; Terbinafine-hydrochloride-patchLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Hisamitsu Pharmaceutical
- Class Amines; Antifungals; Naphthalenes; Skin disorder therapies; Small molecules
- Mechanism of Action Cell membrane modulators; Squalene monooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Onychomycosis
Most Recent Events
- 11 Apr 2013 Terbinafine transdermal is still in phase III trials for Onchomycosis in Japan and phase II trials in US
- 31 Jan 2013 Hisamitsu completes a phase II trial in Onchomycosis in US (NCT01400594)
- 25 Apr 2012 Hisamitsu Pharmaceutical completes a phase III trial in Onychomycosis in Japan